Supplementary Table 2. Baseline characteristics of patients enrolled in included studies

Author, Year	Intervention	Age (years)	Male, n (%)	BMI (kg/m^2)	HbA1c (%)	Liver fat content assessed by MRI-PDFF	Liver stiffness measurement assessed by MRE (kPa)	Diabetes n, (%)	Hypertension n, (%)	Dyslipide-mia, n(%)	Fibrosis stage distributions, n (%)		
											F1	F2	F3
Loomba R, 2023[1]	Placebo (n=71)	56.3±9.0	32 (45)	38.1±5.6	6.6±1.0	16.7±7.1	n.a.	49 (69)	n.a.	n.a.	2 (3)	20 (28)	47 (66)
	Pegozafermin 15 mg weekly (n=21)	55.0±10.5	12 (57)	37.8±4.8	7.0±1.2	15.8±6.4	n.a.	18 (86)	n.a.	n.a.	3 (14)	6 (29)	9 (43)
	Pegozafermin 30 mg weekly (n=73)	55.3±11.2	23 (32)	35.1±6.4	6.6±1.2	16.7±7.0	n.a.	45 (62)	n.a.	n.a.	2 (3)	21 (29)	47 (64)
	Pegozafermin 44 mg every 2 week (n=57)	55.2±11.2	20 (35)	36.1±5.5	6.7±1.3	15.8±7.8	n.a.	35 (61)	n.a.	n.a.	0	21 (37)	30 (53)
Loomba R,	Placebo	57.5±8.0	20 (41)	35.2±8.1	6.9±1.2	12.5±5.9	4.3±1.2	34 (74)	n.a.	n.a.	n.a.	n.a.	49

2024[2]	(n=49)												(100)
	PGBF 10 mg (n=49)	56.4±9.6	20 (41)	36.3±6.7	6.9±1.4	13.9±6.3	4.6±1.8	34 (72)	n.a.	n.a.	n.a.	n.a.	49 (100)
	PGBF 20 mg (n=50)	56.3±10.1	23(46)	35.1±6.4	6.8±1.0	13.4±6.3	4.1±1.1	35 (75)	n.a.	n.a.	n.a.	n.a.	50 (100)
	PGBF 40 mg (n=49)	57.4±10.5	18(37)	35.7±6.6	6.9±1.3	13.0±5.2	4.6±1.6	34 (74)	n.a.	n.a.	n.a.	n.a.	49 (100)
Ratziu V, 2022[3]	Placebo (n=24)	50.8 ± 10.5	13 (54)	36.1 ± 5.5	7.4 ± 0.9 (n=21)	20.4 ± 9.0	3.8 ± 1.2	21 (88)	19 (79)	17 (71)	1 (4)	6 (25)	4 (17)
	EDP-305 1 mg (n=55)	51.5 ± 12.0	26 (47)	34.5 ± 4.9	6.9 ± 1.0 (n=42)	22.0 ± 7.8	3.3 ± 0.8	42 (76)	38 (69)	43 (78)	20 (36)	6 (11)	2 (4)
	EDP-305 2.5 mg (n=53)	52.3 ± 11.8	24 (45)	33.8 ± 5.3	7.4 ± 0.9 (n=34)	18.8 ± 8.1	3.1 ± 0.8	34 (64)	38 (72)	39 (74)	16 (30)	5 (9.4)	9 (17.0)
Harrison SA, 2022[4]	Placebo (n=43)	53·0±10·8	17 (40)	18±42	6.60 ± 1.02	17·0±6·6	n.a	18 (42)	n.a.	n.a.	n.a.	27 (63)	16 (37)
	Aldafermin 0·3 mg (n=43)	54·3±11·2	15 (35)	20±47	6.50 ± 0.81	19·1±7·6	n.a	20 (47)	n.a.	n.a.	n.a.	28 (65)	15 (35)

	Aldafermin 1·0 mg (n=42)	49·8±13·2	13 (31)	22±52	6.30 ± 0.66	17·4±6·4	n.a	22 (52)	n.a.	n.a.	n.a.	27 (64)	15 (36)
	Aldafermin 3·0 mg (n=43)	52·7±11·1	14 (33)	24±56	6.50 ± 0.67	18·7±7·5	n.a	24 (56)	n.a.	n.a.	n.a.	28 (65)	15 (35)
Kuchay MS, 2020[5]	Control (n=32)	48.1±8.9	22 (69)	29.9±3.9	8.4±1.0	17.1±7.7	n.a	32 (100)	5 (16)	12 (38)	n.a.	n.a.	n.a.
	Dulaglutide (n=32)	46.6±9.1	23 (72)	29.6±3.6	8.4±1.0	17.9±7.2	n.a	32 (100)	6 (19)	9 (28)	n.a.	n.a.	n.a.
§Ratziu V, 2023[6]	[a]Placebo QD (n=32)	57.3±10.3	14 (44)	34.31±4.3	6.59±1.0	20.93±7.2	n.a.	19 (59)	19 (59)	n.a.	2 (6)	3 (9)	0
	[a]Vonafexor 100 mg QD (n=31)	58.1±13.7	17 (55)	34.26±4.1	6.47±1.3	19.77±6.3	n.a.	15 (48)	22 (71)	n.a.	2 (7)	0	0
	[a]Vonafexor 200 mg QD (n=33)	54.0±11.9	12 (36)	35.40±5.1	6.33±1.2	20.05±6.7	n.a.	13 (39)	18 (55)	n.a.	0	0	2 (6)
Harrison SA, 2023[7]	Placebo (n=30)	54.8±10.2	9 (30)	36.1±7.4	6.2±0.7	20.1±7.0	n.a.	13 (43)	n.a.	n.a.	10 (33)	n.a.	n.a.
	PXL065 7.5 mg QD (n=25)	50.7±17.3	11 (44)	33.9±5.4	6.2±0.9	22.0±10.5	n.a.	10 (40)	n.a.	n.a.	9 (36)	n.a.	n.a.
	PXL065 15 mg QD	54.1±10.9	14 (44)	37.7±5.9	6.1±0.8	19.5±7.7	n.a.	13 (41)	n.a.	n.a.	11 (34)	n.a.	n.a.

	(n=32)												
	PXL065 22.5 mg QD (n=30)	53.4±12.4	16 (53)	36.4±5.6	6.3±1.1	20.0±7.0	n.a.	12 (40)	n.a.	n.a.	11 (37)	n.a.	n.a.
Harrison SA, 2021[8]	Placebo (n=21)	52.4±9.6	6 (29)	37.6±4.8	6.49±1.0	19.3±6.9	n.a.	14 (67)	n.a.	n.a.	8 (38)	5 (24)	8 (38)
	Efruxifermin 28 mg (n=19)	50.4±12.4	9 (47)	38.8±9.3	6.20±1.0	21.4±8.1	n.a.	7 (37)	n.a.	n.a.	7 (37)	7 (37)	5 (26)
	Efruxifermin 50 mg (n=20)	52.6±14.2	10 (50)	36.7±6.8	6.43±1.2	18.3±6.3	n.a.	10 (50)	n.a.	n.a.	7 (35)	8 (40)	5 (25)
	Efruxifermin 70 mg (n=20)	53.0±13.2	9 (45)	37.2±5.5	6.23±1.2	19.4±6.3	n.a.	10 (50)	n.a.	n.a.	7 (35)	6 (30)	7 (35)
Huang JF, 2021[9]	Placebo (n=47)	43.8±11.9	39 (83)	29.4±4.6	6.1±0.7	21.6±7.5	n.a.	10 (21)	15 (32)	n.a.	18 (38)	3 (6)	5 (11)
	Pioglitazone 30 mg/day (n=43)	43.9±13.7	27 (63)	28.4±2.8	6.0±0.6	20.6±9.3	n.a.	11 (26)	20 (47)	n.a.	18 (42)	1 (2)	5 (12)
Harrison SA, 2021[10]	Placebo (n=25)	54.1±9.7	9 (36)	36.8±9.0	6.7±1.0	18.5±6.8	n.a.	16 (64)	n.a.	n.a.	n.a.	15 (60)	10 (40)
	Aldafermin 1 mg (n=53)	53.0±12.1	27 (51)	35.8±6.3	6.6±1.3	18.0±5.9	n.a.	32 (60)	n.a.	n.a.	n.a.	29 (55)	24 (45)
Patel K, 2020[11]	Placebo	51 (45, 56)	13 (46)	34.2	6.0 (5.6,	19.3	3.12 (2.70,	15 (54)	n.a.	n.a.	n.a.	n.a.	n.a.

	(n=28)			(31.5, 36.0)	7.1)	(13.3, 26.0)	3.65)						
	Cilofexor 30 mg (n=56)	54 (42, 61)	19 (34)	32.7 (29.9, 37.6)	5.9 (5.4, 7.0)	14.9 (9.9, 20.3)	3.23 (2.81, 3.96)	29 (52)	n.a.	n.a.	n.a.	n.a.	n.a.
	Cilofexor 100 mg (n=56)	58 (48, 64)	21 (38)	33.4 (30.3, 36.6)	6.3 (5.7, 7.0)	16.1 (12.3, 18.9)	3.32 (2.87, 4.12)	33 (59)	n.a.	n.a.	n.a.	n.a.	n.a.
Harrison SA, 2023[12]	[b]Placebo DB (n=318)	55.7±12.1	150 (47)	35.2±5.8	n.a.	17.8±6.9	2.60±0.5	159 (50)	242 (76)	281 (88)	n.a.	n.a.	n.a.
	[b]Resmetirom 80 mg DB (n=327)	56.2±11.7	145 (44)	35.3±5.9	n.a.	17.7±6.7	2.6±0.5	160 (49)	249 (76)	288 (88)	n.a.	n.a.	n.a.
	[b]Resmetirom 100 mg DB (n=324)	55.9±11.7	147 (45)	35.4±6.4	n.a.	18.1±7.3	2.6±0.5	156 (48)	246 (76)	283 (87)	n.a.	n.a.	n.a.
Loomba R, 2023[13]	Placebo (n=19)	52.62±8.99	7 (37)	33.80±2.79	n.a.	21.75±9.01	n.a.	12 (63)	n.a.	n.a.	n.a.	n.a.	n.a.
	Pegozafermin 3 mg once weekly (n=6)	56.13±8.23	1 (17)	34.25±5.28	n.a.	22.43±8.47	n.a.	5 (83)	n.a.	n.a.	n.a.	n.a.	n.a.
	Pegozafermin 9 mg once weekly	49.50±11.45	6 (50)	32.73±5.26	n.a.	21.43±6.30	n.a.	4 (33)	n.a.	n.a.	n.a.	n.a.	n.a.

	(n=12)												
	Pegozafermin 18 mg once weekly (n=11)	51.47±13.39	3 (27)	32.77±5.14	n.a.	19.30±6.29	n.a.	7 (64)	n.a.	n.a.	n.a.	n.a.	n.a.
	Pegozafermin 27 mg once weekly (n=10)	51.96±9.83	2 (20)	36.82±4.84	n.a.	22.01±9.19	n.a.	4 (40)	n.a.	n.a.	n.a.	n.a.	n.a.
	Pegozafermin 18 mg once every 2 weeks (n=14)	51.22±8.14	4 (29)	37.01±5.30	n.a.	21.57±8.93	n.a.	3 (21)	n.a.	n.a.	n.a.	n.a.	n.a.
	Pegozafermin 36 mg once every 2 weeks (n=9)	52.46±8.73	8 (89)	34.79±4.73	n.a.	20.94±9.54	n.a.	2 (22)	n.a.	n.a.	n.a.	n.a.	n.a.
†▲Newsome PN, 2021[14]	Placebo (n=80)	52.4±10.8	36 (45)	36.1±6.6	7.3±1.2	n.a.	n.a.	50 (62)	n.a.	n.a.	22 (28)	22 (28)	36 (45)
	Semaglutide 0.1 mg (n=80)	55.2±10.9	29 (36)	36.1±6.4	7.4±1.3	n.a.	n.a.	49 (61)	n.a.	n.a.	23 (29)	18 (22)	39 (49)
	Semaglutide 0.2 mg	58.1±9.9	26 (33)	35.6±6.1	7.2±1.0	n.a.	n.a.	51 (65)	n.a.	n.a.	19 (24)	18 (23)	41 (53)

	(n=78)												
	Semaglutide 0.4 mg (n=82)	54.3±10.2	35 (43)	35.2±6.6	7.2±1.2	n.a.	n.a.	49 (60)	n.a.	n.a.	26 (32)	14 (17)	42 (51)
Calle RA, 2021[15]	[c]Placebo (n=61)	53±11	25 (41)	33.2±4.8	6.3±1.0	19.1±8.0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	[c]PF-05221304 2 mg QD (n=63)	54±12	26 (41)	34.1±4.8	6.1±1.0	17.7±7.0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	[c]PF-05221304 10 mg QD (n=62)	53±13	29 (47)	33.3±4.5	6.2±1.0	18.3±8.0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	[c]PF-05221304 25 mg QD (n=58)	54±12	23 (40)	35.4±6.0	6.2±1.0	18.7±9.0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	PF-05221304 50 mg QD (n=61)	53±13	31 (51)	33.7±5.5	6.2±1.0	18.2±8.0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Harrison SA, 2024[16]	Placebo (n=321)	57.1±10.5	143 (45)	35.3±6.5	n.a.	17.8±6.8	3.5±1.0	210 (65)	257 (80)	224 (70)	18 (6)	112 (35)	191 (60)
	Resmetirom 80 mg (n=322)	55.9±11.5	140 (44)	35.5±6.4	n.a.	18.2±6.8	3.5±0.9	224 (70)	243 (76)	229 (71)	16 (5)	107 (33)	199 (62)
	Resmetirom 100 mg	57.0±10.8	141 (44)	36.2±7.4	n.a.	17.2±6.6	3.7±1.1	213 (66)	254 (79)	236 (73)	15 (5)	100 (31)	208 (64)

	(n=323)												
Nakajima A, 2021[17]	Placebo (n=60)	53.3±16.6	37 (62)	29.8±6.5	6.13±0.68	18.1±5.5	3.02±0.44	25 (42)	n.a.	37 (62)	n.a.	n.a.	n.a.
	Pemafibrate (n=58)	53.2±12.5	31 (53)	29.5±4.9	6.09±0.62	18.7±6.9	3.24±0.81	18 (31)	n.a.	31 (53)	n.a.	n.a.	n.a.
[e]Francque SM, 2021[18]	Placebo (n=81)	53.4±13.1	40 (49)	32.8±5.1	6.0±0.7	n.a.	n.a.	35 (43)	n.a.	n.a.	n.a.	[e]57 (70)	
	Lanifibranor 800 mg (n=83)	55.0±10.4	29 (35)	32.5±5.5	6.1±0.8	n.a.	n.a.	33 (40)	n.a.	n.a.	n.a.	[e]68 (82)	
	Lanifibranor 1200 mg (n=83)	52.2±13.8	34 (41)	33.3±5.5	6.1±0.7	n.a.	n.a.	35 (42)	n.a.	n.a.	n.a.	[e]63 (76)	
Cusi K, 2016[19]	Placebo (n=51)	49±11	35 (69)	34.5±4.8	n.a.	n.a.	n.a.	28 (55)	n.a.	n.a.	22 (43)	4 (8)	n.a.
	Pioglitazone 45 mg/d (n=50)	52±10	36 (72)	34.3±4.8	n.a.	n.a.	n.a.	24 (48)	n.a.	n.a.	22 (44)	6 (12)	n.a.
Armstrong MJ, 2016[20]	Placebo (n=7)	56.0 (39.0, 59.0)	4 (57)	36.5 (29.3, 40.0)	5.5 (5.3, 6.3)	n.a.	n.a.	3 (43)	n.a.	n.a.	n.a.	n.a.	n.a.
	Liraglutide (n=7)	59.0 (57.0, 60.0)	5 (71)	34.0 (30.7, 35.9)	6.0 (5.6, 6.4)	n.a.	n.a.	4 (57)	n.a.	n.a.	n.a.	n.a.	n.a.

Armstrong MJ, 2016[21]	Placebo (n=26)	52±12	13 (50)	37.7±6.2	6.0±0.9	n.a.	n.a.	8 (31)	14 (54)	7 (27)	[f]11 (42)		[g]15 (58)
	Liraglutide (n=26)	50±11	18 (69)	34.2±4.7	5.9±0.7	n.a.	n.a.	9 (35)	15 (58)	9 (35)	[f]14 (54)		[g]12 (46)
Neuschwander-Tetri BA, 2015[22]	Placebo (n=142)	51±12	53 (37)	34±6	6.45±1.01	n.a.	n.a.	74 (52)	85 (60)	86 (61)	n.a.	n.a.	n.a.
	Obeticholic acid 25 mg (n=141)	52±11	43 (30)	35±7	6.54 ± 1.10	n.a.	n.a.	75 (53)	87 (62)	87 (62)	n.a.	n.a.	n.a.
Harrison SA, 2019[23]	Placebo (n=41)	47.3±11.7	24 (59)	33.6±5.8	2.70 ± 0.08	19.6±8.2	n.a.	13 (32)	18 (44)	n.a.	19 (46)	13 (32)	7 (17)
	Resmetirom (n=84)	51.8±10.4	38 (45)	35.8±6.2	2.73 ± 0.11	20.2±6.8	n.a.	36 (43)	45 (54)	n.a.	47 (56)	18 (21)	18 (21)
Sanyal A, 2018[24]	Placebo (n=26)	47±12	10 (38)	37±7	6.0±0.9	21±7	3.1±1.2	11 (42)	n.a.	n.a.	17 (65)	8 (31)	1 (4)
	Pegbelfermin 10 mg once-daily (n=25)	52±10	10 (40)	34±4	6.1±0.9	18±7	3.5±1.4	9 (36)	n.a.	n.a.	10 (40)	6 (24)	9 (36)
	Pegbelfermin 20 mg once-weekly (n=24)	52±12	7 (29)	35±6	6.2±1.1	20±6	3.4±1.0	8 (33)	n.a.	n.a.	13 (54)	6 (25)	5 (21)
Loomba R,	Placebo	58 (49, 64)	7 (27)	33 (28,	6.0 (5.7,	13.6 (9.4,	3.46 (3.15,	15 (58)	n.a.	n.a.	n.a.	n.a.	n.a.

2018[25]	(n=26)			35)	8.2)	15.2)	4.20)						
	GS-0976 5 mg (n=51)	55 (47, 61)	21 (41)	33 (30, 36)	5.9 (5.4, 6.8)	15.7 (11.3, 19.6)	3.42 (2.89, 4.47)	29 (57)	n.a.	n.a.	n.a.	n.a.	n.a.
	GS-0976 20 mg (n=49)	56 (46, 62)	16 (33)	33 (28, 37)	6.5 (5.8, 7.8)	15.9 (10.9, 20.1)	3.40 (2.96, 3.99)	32 (65)	n.a.	n.a.	n.a.	n.a.	n.a.
Harrison SA, 2018[26]	Placebo (n=27)	52.8±11.3	7 (26)	35.6±5.8	6.7±1.4	16.8±6.7	n.a.	17 (63)	21 (78)	8 (30)	11 (41)	7 (26)	9 (33)
	NGM282 3 mg (n=27)	52.0±7.1	11 (41)	34.0±8.7	6.5±1.0	18.1±7.3	n.a.	15 (56)	15 (56)	10 (37)	11 (41)	7 (26)	9 (33)
	NGM282 6 mg (n=28)	56.4±7.8	12 (43)	34.7±5.5	6.7±1.2	19.5±7.8	n.a.	17 (61)	18 (64)	15 (54)	10 (36)	12 (43)	6 (21)
Ratziu V, 2016[27]	Placebo (n=92)	52.4±11.9	55 (60)	30.9±4.2	6.0±0.8	n.a.	n.a.	33 (36)	43 (47)	50 (54)	32 (35)	25 (27)	20 (22)
	Elafibranor 80 mg (n=93)	52.7±11.0	49 (53)	31.8±5.2	6.0±0.9	n.a.	n.a.	37 (40)	47 (50)	46 (49)	28 (30)	22 (24)	23 (25)
	Elafibranor 120 mg (n=89)	52.4±11.6	47 (53)	31.0±4.4	6.2±1.1	n.a.	n.a.	37 (42)	55 (62)	58 (65)	39 (44)	25 (28)	20 (22)
Sanyal AJ, 2023[28]	[d]Placebo (n=825)	54.4±11.2	347 (42)	34.1±5.5	n.a.	n.a.	n.a.	470 (57)	554 (67)	n.a.	n.a.	n.a.	n.a.
	[d]Obeticholic acid 10 mg	55.3±10.8	350 (42)	33.7±5.6	n.a.	n.a.	n.a.	476 (58)	549 (67)	n.a.	n.a.	n.a.	n.a.

	(n=825)												
	[d]Obeticholic acid 25 mg (n=827)	55.3±11.7	333 (40)	33.7±5.5	n.a.	n.a.	n.a.	479 (58)	537 (65)	n.a.	n.a.	n.a.	n.a.
Alkhouri N, 2022[29]	Semaglutide 2.4 mg (n=21)	57 (51, 61)	6 (29)	33.2 (30.9, 36.4)	6.1 (5.8, 6.7)	15.3 (9.9, 19.5)	2.8 (2.4, 3.3)	11 (52)	n.a.	n.a.	n.a.	n.a.	n.a.
	Semaglutide 2.4 mg + cilofexor 30 mg (n=22)	53 (46, 58)	6 (27)	34.0 (32.7, 36.0)	6.3 (5.7, 7.7)	19.3 (13.5, 27.1)	3.0 (2.3, 3.8)	12 (55)	n.a.	n.a.	n.a.	n.a.	n.a.
	Semaglutide 2.4 mg + cilofexor 100 mg (n=22)	58 (46, 61)	9 (41)	34.1 (29.7, 39.4)	6.5 (5.6, 7.8)	18.0 (14.5, 23.9)	2.5 (2.4, 3.0)	12 (55)	n.a.	n.a.	n.a.	n.a.	n.a.
	Semaglutide 2.4 mg + firsocostat 20 mg (n=22)	53 (47, 60)	7 (32)	33.5 (30.2, 37.9)	6.3 (5.9, 7.3)	18.1 (12.5, 24.3)	3.0 (2.6, 3.8)	13 (59)	n.a.	n.a.	n.a.	n.a.	n.a.
	Semaglutide 2.4 mg + cilofexor 30 mg +	53 (49, 61)	6 (29)	39.5 (34.3, 43.0)	6.3 (5.9, 7.5)	15.9 (12.3, 25.4)	2.9 (2.6, 3.6)	11 (52)	n.a.	n.a.	n.a.	n.a.	n.a.

	firsocostat 20 mg (n=21)												
Younossi ZM, 2019[30]	Placebo (n=311)	55±12	124 (40)	n.a.	6.6±1.2	n.a.	n.a.	175 (56)	215 (69)	211 (68)	n.a.	142 (46)	169 (54)
	Obeticholic acid 10 mg (n=312)	55±11	135 (43)	n.a.	6.5±1.2	n.a.	n.a.	171 (55)	215 (69)	217 (70)	n.a.	130 (42)	182 (58)
	Obeticholic acid 25 mg (n=308)	55±11	133 (43)	n.a.	6.5±1.3	n.a.	n.a.	171 (56)	196 (64)	205 (67)	n.a.	139 (45)	169 (55)
Mudaliar S, 2013[31]	Placebo (n=23)	53.1±12.1	10 (43)	36.1±7.4	7.6±1.2	n.a.	n.a.	23 (100)	n.a.	n.a.	n.a.	n.a.	n.a.
	Obeticholic acid 25 mg (n=20)	52.7±8.7	14 (70)	36.5±6.2	7.4±1.3	n.a.	n.a.	20 (100)	n.a.	n.a.	n.a.	n.a.	n.a.
	Obeticholic acid 50 mg (n=21)	50.5±10.8	9 (43)	36.5±7.9	7.0±1.4	n.a.	n.a.	21 (100)	n.a.	n.a.	n.a.	n.a.	n.a.
V. Ratziu, 2008[32]	Placebo (n=31)	54.1±10.4	18 (58)	30.5±4.4	5.6±0.9	n.a.	n.a.	11 (35)	13 (42)	13 (43)	n.a.	n.a.	n.a.
	Rosiglitazone (n=32)	53.1±11.5	19 (59)	31.56±6	5.6±1.03	n.a.	n.a.	9 (28)	10 (31)	10 (31)	n.a.	n.a.	n.a.
†Romero-Gómez M, 2023[33]	Efinopegdutide (n=72)	48.1±11.0	39 (54)	35.2±5.7	6.3±0.7	21.1±8.1	n.a.	24 (33)	n.a.	n.a.	n.a.	n.a.	n.a.

	Semaglutide (n=73)	50.9 ±10.9	41 (56)	33.5±5.0	6.5±0.8	19.4±8.1	n.a.	24 (33)	n.a.	n.a.	n.a.	n.a.	n.a.
Siddiqui MS, 2021[34]	Overall (n=16)	52±14	2 (13)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
T. Gawrieh, 2021[35]	Placebo (n=28)	48.7±10.5	15 (54)	33.8±4.5	6.2±1.0	24.8±10.4	n.a.	16 (57)	n.a.	n.a.	n.a.	n.a.	n.a.
	Saroglitazar 1 mg (n=26)	51.1±12.9	13 (50)	33.6±4.2	5.9±0.7	20.2±8.9	n.a.	11 (42)	n.a.	n.a.	n.a.	n.a.	n.a.
	Saroglitazar 2 mg (n=25)	47.9±10.4	13 (52)	35.7±8.6	6.8±1.5	23.9±8.9	n.a.	17 (68)	n.a.	n.a.	n.a.	n.a.	n.a.
	Saroglitazar 4 mg (n=27)	49.0±11.0	15 (56)	32.5±5.2	6.1±0.9	22.8±8.5	n.a.	12 (44)	n.a.	n.a.	n.a.	n.a.	n.a.
†Harrison SA, 2024[36]	Placebo (n=24)	47.9±14	10 (42)	36.9±4.7	6.2±0.6	23.8±9.2	n.a.	6 (25)	n.a.	n.a.	n.a.	n.a.	n.a.
	1.2 mg pemvidutide (n=23)	48.6±11	9 (39)	36.3±5.6	6.6±1.4	21.6±7.3	n.a.	7 (30)	n.a.	n.a.	n.a.	n.a.	n.a.
	1.8 mg pemvidutide (n=23)	50.3±9	9 (39)	35.4±3.9	6.4±0.5	21.8±8.0	n.a.	7 (30)	n.a.	n.a.	n.a.	n.a.	n.a.
	2.4 mg pemvidutide (n=24)	48.8±8	10 (42)	35.3±5.0	7.5±1.3	20.2±7.0	n.a.	7 (29)	n.a.	n.a.	n.a.	n.a.	n.a.
Sanyal AJ, 2024[37]	Placebo (n=74)	53.0±11.5	30 (41)	35.49±6.44	7.08±0.87	19.62±7.59	n.a.	29 (39)	n.a.	n.a.	14 (19)	30 (41)	30 (41)

	Survodutide 2.4 mg (n=73)	49.6±13.7	37 (51)	35.30±5.05	6.90±1.12	19.75±7.56	n.a.	28 (38)	n.a.	n.a.	20 (27)	30 (41)	23 (32)
	Survodutide 4.8 mg (n=72)	50.2±12.9	38 (53)	35.00±6.97	6.90±1.06	21.09±8.26	n.a.	26 (36)	n.a.	n.a.	13 (18)	36 (50)	23 (32)
	Survodutide 6.0 mg (n=74)	50.4±13.1	33 (45)	37.42±6.84	6.92±0.91	17.85±6.34	n.a.	30 (41)	n.a.	n.a.	23 (31)	24 (32)	27 (36)
Shankar SS, 2024[38]	Placebo (n=24)	52.2±13.5	10 (42)	37.6±5.1	6.8±1.5	19.1±8.2	n.a.	12 (50)	n.a.	n.a.	7 (29.2)	14 (58.3)	3 (12.5)
	Cotadutide 300 mg (n=25)	55.9±10.5	13 (52)	37.3±7.1	6.7±1.1	20.3±8.7	n.a.	16 (64)	n.a.	n.a.	8 (32.0)	13 (52.0)	4 (16.0)
	Cotadutide 600 mg (n=25)	59.4±11.9	10 (40)	37.0±5.3	6.6±1.2	18.7±6.2	n.a.	13 (52)	n.a.	n.a.	3 (12.0)	17 (68.0)	5 (20.0)
Loomba R, 2024[39]	Placebo (n=48)	53.5±11.6	21 (44)	36.0±6.7	6.8±1.2	18.2±6.8	n.a.	29 (60)	n.a.	n.a.	n.a.	17 (35)	31 (65)
	Tirzepatide 5 mg (n=47)	55.0±11.6	20 (43)	36.1±6.0	6.6±1.3	19.0±6.9	n.a.	26 (55)	n.a.	n.a.	n.a.	17 (36)	30 (64)
	Tirzepatide 10 mg (n=47)	54.3±12.1	21 (45)	36.6±6.3	6.4±1.1	17.6±7.5	n.a.	27 (57)	n.a.	n.a.	n.a.	25 (53)	22 (47)

	Tirzepatide 15 mg (n=48)	54.9±10.0	19 (40)	35.9±5.7	6.4±0.9	18.8±8.3	n.a.	29 (60)	n.a.	n.a.	n.a.	22 (46)	26 (54)
Sanyal AJ, 2024[40]	Placebo (n=19)	45.5±10.7	9 (47)	38.6±4.6	5.56±0.33	15.6±5.8	n.a.	0 (0)	n.a.	n.a.	n.a.	n.a.	n.a.
	Retatrutide 1 mg (n=20)	50.4±13.1	11 (55)	38.6±5.6	5.62±0.40	19.5±6.3	n.a.	0 (0)	n.a.	n.a.	n.a.	n.a.	n.a.
	Retatrutide 4 mg (n=19)	45.3±10.0	11 (58)	38.3±4.7	5.63±0.36	18.9±6.8	n.a.	0 (0)	n.a.	n.a.	n.a.	n.a.	n.a.
	Retatrutide 8 mg (n=22)	47.7±11.6	13 (59)	37.1±4.9	5.63±0.38	20.9±7.8	n.a.	0 (0)	n.a.	n.a.	n.a.	n.a.	n.a.
	Retatrutide 12 mg (n=18)	43.4±14.3	8 (44)	39.7±6.1	5.45±0.43	20.5±6.7	n.a.	0 (0)	n.a.	n.a.	n.a.	n.a.	n.a.
Newsome PN, 2024[41]	Placebo (n=266)	55.4±12.0	122 (46)	35.0±7.1	6.4±1.0	n.a	n.a	151 (57)	n.a	n.a	n.a.	n.a.	185 (69.5)
	Semaglutide 2.4 mg (n=534)	56.3±11.4	221 (41)	34.3±7.2	6.6±1.1	n.a	n.a	296 (55)	n.a	n.a	n.a.	n.a.	365 (68.4)
Loomba R, 2024[42]	Placebo (n=62)	53	24 (39)	37	n.a	n.a	n.a	25 (40)	n.a	n.a	18 (29)	22 (35)	22 (36)
	VK2809 1.0 mg QD (n=17)	52	8 (47)	38	n.a	n.a	n.a	4 (24)	n.a	n.a	4 (24)	7 (41)	6 (35)

	VK2809 2.5 mg QD (n=59)	53	26 (44)	36	n.a	n.a	n.a	26 (44)	n.a	n.a	18 (30)	20 (34)	21 (36)
	VK2809 5.0 mg QOD (n=36)	53	16 (44)	37	n.a	n.a	n.a	18 (50)	n.a	n.a	8 (22)	15 (42)	13 (36)
	VK2809 10.0 mg QOD (n=57)	52	24 (42)	37	n.a	n.a	n.a	27 (47)	n.a	n.a	18 (32)	19 (33)	20 (35)
†Noureddin M, 2024[43]	Placebo (n=41)	55±10	20 (49)	37±6	7.1±1.2	21.8±6.7	n.a	20 (49)	n.a	n.a	n.a.	n.a.	18 (44)
	Efimosfermin 300 mg Q4W (n=43)	53±12	20 (46)	38±6	7.1±1.1	19.5±8.1	n.a	28 (65)	n.a	n.a	n.a.	n.a.	19 (42)
You H, 2024[44]	Placebo (n=21)	37.1±10.7	17 (81)	29.8±3.5	n.a	18.5±6.2	n.a	4 (19)	n.a	n.a	n.a	n.a	n.a
	Chiglitazar 48 mg (n=42)	40.4±1.1	33 (79)	29.0±3.7	n.a	20.2±7.8	n.a	10 (24)	n.a	n.a	n.a	n.a	n.a
	Chiglitazar 64 mg (n=41)	40.1±9.4	29 (71)	29.5±3.9	n.a	19.5±7.2	n.a	8 (20)	n.a	n.a	n.a	n.a	n.a

Note: Continuous data are presented as mean±standard deviations, mean, or median (interquartile range), and categorical variables are expressed by the number (proportions). Fibrosis stage distributions identified by liver biopsy were extracted. n.a.: not applicable. a. part B of this study; b. only for individuals in double-blind set; c. part A of this study; d. interim analysis; e: Refer to fibrosis stage F2 or F3; f: Refer to Fibrosis stage F0-F2; g: Refer to Fibrosis stage F3-F4. †: HbA1c only for patients

within diabetes subgroup. ▲: BMI was presented as geometric means±coefficient of variation in the original study; §: There were 27 (84.4%), 29 (93.6%), 31 (93.9%) individuals in groups with placebo, Vonafexor 100 mg QD, and Vonafexor 200 mg QD were not biopsy available.

References:

1. Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. Journal article. New England journal of medicine. 2023;389(11):998-1008. doi:10.1056/NEJMoa2304286
2. Loomba R, Sanyal AJ, Nakajima A, et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study. Journal article. Clinical gastroenterology and hepatology. 2024;22(1):102-112.e9. doi:10.1016/j.cgh.2023.04.011
3. Ratziu V, Rinella ME, Neuschwander-Tetri BA, et al. EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study. Journal article. Journal of hepatology. 2022;76(3):506-517. doi:10.1016/j.jhep.2021.10.018
4. Harrison SA, Abdelmalek MF, Neff G, et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Journal article. The lancet Gastroenterology & hepatology. 2022;7(7):603-616. doi:10.1016/S2468-1253(22)00017-6
5. Kuchay MS, Krishan S, Mishra SK, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Journal article. Diabetologia. 2020;63(11):2434-2445. doi:10.1007/s00125-020-05265-7
6. Ratziu V, Harrison SA, Loustaud-Ratti V, et al. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. Journal article. Journal of hepatology. 2023;78(3):479-492. doi:10.1016/j.jhep.2022.10.023
7. Harrison SA, Thang C, Bolze S, et al. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1). Journal article. Journal of hepatology. 2023;78(5):914-925. doi:10.1016/j.jhep.2023.02.004
8. Harrison SA, Ruane PJ, Freilich BL, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Journal article. Nature medicine. 2021;27(7):1262-1271. doi:10.1038/s41591-021-01425-3
9. Huang JF, Dai CY, Huang CF, et al. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. Journal article. Hepatology international. 2021;15(5):1136-1147. doi:10.1007/s12072-021-10242-2
10. Harrison SA, Neff G, Guy CD, et al. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Journal article. Gastroenterology. 2021;160(1):219-231.e1. doi:10.1053/j.gastro.2020.08.004
11. Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Article. Hepatology. Jul 2020;72(1):58-71. doi:10.1002/hep.31205
12. Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Article; Early Access. Nature Medicine. 2023 Oct 2023:29. doi:10.1038/s41591-023-02603-1
13. Loomba R, Lawitz EJ, Frias JP, et al. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Journal article. The lancet Gastroenterology & hepatology. 2023;8(2):120-132. doi:10.1016/S2468-1253(22)00347-8
14. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. Article. New England Journal of Medicine. Mar 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395

15. Calle RA, Amin NB, Carvajal-Gonzalez S, et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Journal article. Nature medicine. 2021;27(10):1836-1848. doi:10.1038/s41591-021-01489-1
16. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. Article. New England Journal of Medicine. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000
17. Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. Article; Early Access. Aliment Pharmacol Ther. 2021 2021;54(10):1263-1277. doi:10.1111/apt.16596
18. Francque SM, Bedossa P, Ratziu V, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. Journal article. New England journal of medicine. 2021;385(17):1547-1558. doi:10.1056/NEJMoa2036205
19. Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. Annals of Internal Medicine. 2016;165(5)doi:10.7326/m15-1774
20. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of Hepatology. 2016;64(2):399-408. doi:10.1016/j.jhep.2015.08.038
21. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet. 2016;387(10019):679-690. doi:10.1016/s0140-6736(15)00803-x
22. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet. 2015;385(9972):956-965. doi:10.1016/s0140-6736(14)61933-4
23. Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2019;394(10213):2012-2024. doi:10.1016/s0140-6736(19)32517-6
24. Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet. 2018;392(10165):2705-2717. doi:10.1016/s0140-6736(18)31785-9
25. Loomba R, Kayali Z, Noureddin M, et al. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018;155(5):1463-1473.e6. doi:10.1053/j.gastro.2018.07.027
26. Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2018;391(10126):1174-1185. doi:10.1016/s0140-6736(18)30474-4
27. Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150(5):1147-1159.e5. doi:10.1053/j.gastro.2016.01.038
28. Sanyal AJ, Ratziu V, Loomba R, et al. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. Journal article. Journal of hepatology. 2023;79(5):1110-1120. doi:10.1016/j.jhep.2023.07.014
29. Alkhouri N, Herring R, Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. Journal article. Journal of hepatology. 2022;77(3):607-618. doi:10.1016/j.jhep.2022.04.003

30. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. 2019;394(10215):2184-2196. doi:10.1016/s0140-6736(19)33041-7
31. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2013;145(3):574-582.e1. doi:10.1053/j.gastro.2013.05.042
32. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135(1):100-110. doi:10.1053/j.gastro.2008.03.078
33. Romero-Gómez M, Lawitz E, Shankar RR, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. Oct 2023;79(4):888-897. doi:10.1016/j.jhep.2023.05.013
34. Siddiqui MS, Idowu MO, Parmar D, et al. A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. Short Survey. Clinical Gastroenterology and Hepatology. 2021;19(12):2670-2672. doi:10.1016/j.cgh.2020.10.051
35. Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: a Randomized Controlled Double-Blind Phase 2 Trial. Journal article. Hepatology (Baltimore, Md). 2021;74(4):1809-1824. doi:10.1002/hep.31843
36. Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. Jul 11 2024;doi:10.1016/j.jhep.2024.07.006
37. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. Journal article. New England journal of medicine. 2024;391(4):311-319. doi:10.1056/NEJMoa2401755
38. Shankar SS, Daniels SJ, Robertson D, et al. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clin Gastroenterol Hepatol. Sep 2024;22(9):1847-1857.e11. doi:10.1016/j.cgh.2024.04.017
39. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. Jul 25 2024;391(4):299-310. doi:10.1056/NEJMoa2401943
40. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Journal article. Nature medicine. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
41. P.N. Newsome, A. J. Sanyal, I. Kliers, L.H Ostergaard, M.T. Long, M.S. Kjaer, A.M.G. Cali, E. Bugianesi5, M. Rinella, M. Roden, V. Ratziu. Phase 3 ESSENCE trial: Semaglutide in metabolic dysfunction-associated steatohepatitis. AASLD. 2024.
42. Loomba R ea. Results from the 52 Week Phase 2b VOYAGE Trial of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized,Placebo-Controlled Trial. AASLD. 2024.
43. Noureddin M ea. Once-monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-associated Steatohepatitis with F2/F3 Fibrosis: Results from a 24 Week, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial. AASLD. 2024.
44. You H ea. A randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of chiglitazar in NASH patients. AASLD. 2024.